GT-216

N/A

Report date: 2026/04/17 10:36:37

Base Information

Drug NameGT-216
Drug Alias NameGT216GT-216
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShanghai Grit Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Grit Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A